Spravato Treatment Process: The Complete Step-by-Step Patient Guide

Spravato, the esketamine nasal spray, offers a vital, targeted option for individuals living with treatment-resistant depression (TRD) who have not found relief with traditional medications.

 

Understanding the entire journey—from confirming your eligibility criteria and navigating necessary medical precautions to adhering to the precise three-phase dosing schedule—ensures you are fully prepared for this advanced neurobiological approach. You will learn precisely what to expect during the mandatory two-hour clinical sessions, how the REMS safety protocols govern your care, and how this treatment integrates with your ongoing mental health management.

 

By mastering the step-by-step process outlined here, you move confidently toward maximizing the potential benefits of your prescribed treatment plan.

 

What is Spravato and How Does it Work?

The Science of Esketamine

Spravato (esketamine) is an FDA-approved nasal spray designed specifically for adults with treatment-resistant depression. It works by targeting the NMDA receptor in the brain, which regulates the production of glutamate. Glutamate is the brain’s most abundant chemical messenger and plays a vital role in mood regulation, as shown in Esketamine for Treatment-Resistant Depression clinical data.

 

One of the most significant benefits of this medication is its impact on neuroplasticity. In plain English, neuroplasticity is the brain’s ability to repair and rewire itself. Chronic depression can damage the connections between brain cells; Spravato helps regrow these pathways, allowing the brain to communicate more effectively and build resilience against depressive symptoms.

 

While traditional antidepressants (like SSRIs or SNRIs) focus on serotonin and can take several weeks to work, the Spravato treatment process triggers a much faster response. By focusing on the glutamate system rather than just serotonin, it can provide relief within hours or days for many patients who have not responded to other medications.

 

Because this treatment targets the brain in such a unique way, it is reserved for patients who meet specific clinical criteria. In the next section, we will explore the requirements to determine if you are eligible for this innovative therapy.

 

Who Qualifies for Spravato Treatment?

The spravato treatment process begins with a thorough evaluation to ensure patients meet specific FDA-approved clinical criteria. Because Spravato (esketamine) is a potent medication administered under the Risk Evaluation and Mitigation Strategy (REMS) program, it is reserved for individuals who have not found relief through traditional mental health therapies.

 

TRD Criteria

The primary indication for Spravato is Treatment-Resistant Depression (TRD). This classification is specific and requires a documented history of medication trials. To qualify under this category, a patient must generally meet the following requirements:

 

• Adult Status: Must be 18 years of age or older.

• Medication History: Must have failed to respond to at least two different oral antidepressants of adequate dose and duration during the current depressive episode.

• Concurrent Treatment: Spravato is intended to be used in conjunction with a newly initiated or existing oral antidepressant.

 

Additionally, Spravato is FDA-approved for adults with Major Depressive Disorder (MDD) who are experiencing acute suicidal ideation or behavior, providing a rapid-acting option for those in crisis.

 

Medical Contraindications

Before beginning treatment, our clinical team at PremierMD performs a comprehensive physical health review. Certain Contraindications may prevent a patient from safely receiving esketamine due to the risk of increased blood pressure or vascular stress during the session.

 

Patients with the following conditions are generally disqualified from treatment:

 

• Aneurysmal vascular disease, including thoracic or abdominal aortic, intracranial, or peripheral arterial aneurysms.

• Arteriovenous malformations (AVMs).

• A history of intracerebral hemorrhage (bleeding in the brain).

• Uncontrolled hypertension, as Spravato can cause transient but significant spikes in blood pressure.

• Known hypersensitivity or allergy to esketamine, ketamine, or any of the device excipients.

 

Mental Health Screening

A critical component of the spravato treatment process is a specialized mental health screening. We evaluate patients for a history of active substance use disorders, particularly those involving stimulants or opioids, as these can complicate the safety and efficacy of the treatment.

 

During this screening, we also assess for a history of psychosis or bipolar disorder, as dissociative anesthetics may exacerbate certain symptoms. Our goal is to ensure that Spravato is the most appropriate and safest intervention for your unique psychiatric profile.

 

[insert checklist of Spravato eligibility requirements here]

 

The Three Phases of the Spravato Protocol

Understanding the Spravato treatment process is essential for managing your expectations and committing to a schedule that yields the best clinical results. The protocol is structured into three distinct stages designed to first stabilize your mood and then sustain those improvements over time.

 

The Induction Phase

The first four weeks of treatment are known as the Induction Phase. During this period, sessions are scheduled twice weekly. This frequent dosing is critical because it works to rapidly “reset” certain neural pathways in the brain that have been affected by chronic depression. Because Spravato targets the glutamate system, this intensive start allows many patients to experience a noticeable lift in symptoms much faster than with traditional oral antidepressants. At PremierMD, we closely monitor your initial response during these eight sessions to ensure the medication is working effectively for your specific needs.

 

Optimization and Maintenance

Following the first month, the frequency of your visits will begin to decrease as you enter the Optimization Phase (Weeks 5 through 8). During this time, treatments typically transition to once weekly. This stage is designed to solidify the progress made during induction while assessing how long the therapeutic effects last between doses.

 

Once you reach Week 9 and beyond, you enter the Maintenance Phase. At this point, dosing is further individualized. Some patients continue with weekly sessions, while others may move to once every two weeks, depending on their symptom stability. The goal of maintenance is to prevent relapse and ensure long-term remission from treatment-resistant depression.

 

[insert Infographic/Timeline Chart here: A horizontal timeline showing Weeks 1-4 (Induction: 2x/week), Weeks 5-8 (Optimization: 1x/week), and Week 9+ (Maintenance: 1x/week or every 2 weeks)]

 

While the spravato treatment process is a long-term commitment, the timeline for seeing results is often encouraging. According to clinical data, many patients experience a reduction in depressive symptoms within the first 24 to 48 hours, with roughly 83% of patients showing significant improvement within the first month. It is important to remember that while early relief is common, completing the full protocol is necessary to achieve the lasting chemical changes in the brain required for sustained mental health.

 

Preparing for Your First Spravato Appointment

Preparing properly is a vital part of the spravato treatment process to ensure both your safety and your comfort. Because esketamine can cause temporary changes in perception and physical coordination, following the clinical guidelines helps minimize risks and allows you to focus fully on your recovery.

 

Pre-Treatment Checklist

To ensure a smooth session, please refer to this mandatory checklist before arriving at our center. These rules are strictly enforced for patient safety, particularly regarding the prevention of [nausea and dizziness](https://www.spravatonj.com/Spravato-Side-Effects.html).

 

| Category | Requirement | Why It Is Mandatory |

| :— | :— | :— |

| Food Intake | No food for at least 2 hours before your appointment. | Prevents nausea and vomiting during treatment. |

| Liquid Intake | No liquids for at least 30 minutes before your appointment. | Reduces the risk of stomach upset and frequent bathroom breaks. |

| Transportation | A mandatory driver must take you home. | Esketamine causes temporary impairment and sedation. |

| Recovery Time | No driving until the following day. | You must have a full night of restful sleep before operating a vehicle. |

 

Managing Medications

Most patients continue their current oral antidepressants while undergoing the spravato treatment process. During your initial consultation, our clinical team will review your full medication list. It is important to:

 

• Inform us of any changes to your prescriptions.

• Discuss any blood pressure medications, as Spravato can cause a temporary rise in blood pressure.

• Avoid taking any nasal corticosteroids or decongestants for at least one hour before your treatment.

 

If you have specific questions about how your current medications interact with treatment, please visit our Spravato FAQ.

 

Transportation Requirements

You cannot drive yourself home after a Spravato session. This is a non-negotiable safety requirement established by the FDA’s REMS program. Because the medication can cause dissociation, dizziness, and sedation, you must have a responsible adult available to drive you from the office directly to your home.

 

[insert illustrative icon or image showing a “no driving” symbol here]

 

Driving Restrictions

The restrictions on operating heavy machinery or vehicles extend beyond the two-hour observation period. You are prohibited from driving or operating machinery until the day after your treatment session, following a full night of restful sleep. Please plan your work and personal schedule accordingly to ensure you have adequate time to rest and recover.

 

What to Expect During the 2-Hour Treatment Session

At PremierMD, we understand that the spravato treatment process can feel unfamiliar, and it is natural to have questions about the time spent in our office. Our goal is to provide a supportive, calm, and safe environment where you can focus entirely on your healing. Each session is designed to be a restful experience, ensuring both your physical safety and your emotional comfort.

 

Clinical Vitals Check

Before your treatment begins, a member of our medical team will conduct a brief clinical vitals check. This is a standard safety protocol where we measure your blood pressure and heart rate to ensure you are in an optimal state for the session. Because Spravato can cause a temporary increase in blood pressure, these checks are repeated at specific intervals—typically at the 40-minute mark and again at the conclusion of your session—to ensure you are ready to be discharged safely.

 

The Administration Process

The administration process is straightforward and non-invasive. Unlike traditional IV ketamine, Spravato is a nasal spray that you will self-administer under the direct supervision of our healthcare professionals.

 

You will be provided with the device and guided through the correct technique to ensure the medication is delivered effectively. Depending on your personalized dose, you may use up to three devices, with a five-minute rest between each one. This controlled approach allows the medication to be absorbed gradually, helping you ease into the treatment experience.

 

The 2-Hour Observation Period

The 2-hour observation period is a mandatory safety requirement, but many of our patients come to view it as a dedicated “time-out” from the stresses of daily life. We recommend bringing items that help you relax, such as a soft blanket, noise-canceling headphones, or an eye mask.

 

Dissociation and Relaxation

During the session, it is common to experience a sensation known as dissociation. For most, this feels like a neutral, transient shift in perception, such as feeling light, “dreamy,” or slightly disconnected from your immediate surroundings. These effects are temporary and typically peak shortly after administration before fading toward the end of the two hours. Many patients describe this time as a period of deep relaxation or introspection.

 

Continuous Medical Supervision

Your safety is our absolute priority. A medical professional is present throughout the entire 2-hour session to monitor your progress and provide support. Whether you need a glass of water, a clinical check-in, or simply the reassurance of a professional nearby, our team at Spravato Treatment Centers of NJ is there to ensure your experience is steady and secure. You are never left alone during the active phase of the medication, allowing you to relax fully into the process.

 

[insert image of a peaceful, comfortable Spravato treatment room here]

 

Who Qualifies for Spravato Treatment?

 

Safety, Side Effects, and REMS Monitoring

The Spravato treatment process is governed by strict federal safety guidelines to ensure every patient receives care in a controlled, clinical environment. Because Spravato (esketamine) is a potent medication that can cause transient changes in consciousness and physical sensation, understanding the safety protocols is essential for a successful recovery journey.

 

Common Side Effects

While most side effects are temporary and typically resolve within the two-hour observation period, patients should be aware of what they may experience during and immediately following administration.

 

[insert chart of common Spravato side effects and their duration here]

 

Common side effects include:

• Nausea and occasional vomiting

• Dizziness or a spinning sensation (vertigo)

• Dissociation (feeling disconnected from yourself, your thoughts, or your surroundings)

• Sedation (feeling extremely sleepy or drowsy)

• Metallic taste

• Headache

• Lethargy or decreased energy

• Feeling “drunk” or uncoordinated

 

Blood Pressure Management

A critical component of the Spravato treatment process involves cardiovascular monitoring. It is common for patients to experience temporary blood pressure spikes shortly after the medication is administered. These elevations usually peak around 40 minutes post-dose and subside within two hours.

 

Important Warning for Hypertensive Patients: If you have a history of high blood pressure (hypertension) or cardiovascular disease, your condition must be stable and well-controlled before beginning treatment. Patients with uncontrolled hypertension or certain pre-existing vascular conditions may be at a higher risk of complications. Our clinical team at PremierMD performs blood pressure checks before administration and multiple times during the observation period to ensure your safety.

 

Understanding REMS

Because of the risks of sedation, dissociation, and the potential for misuse, Spravato is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS). This program is mandated by the FDA to ensure that the medication is only administered in a certified healthcare setting under direct medical supervision.

 

Under the REMS requirements, patients are never permitted to take Spravato home. The program ensures that every administration is tracked and that the facility is equipped to monitor patients for at least two hours following each dose. For more detailed information on these federal guidelines, you can review the Spravato REMS Program Safety Information.

 

Long-Term Side Effects

While many side effects are acute and short-lived, researchers continue to monitor the long-term impact of esketamine use. One specific area of focus is the potential for bladder issues, also known as cystitis. Some patients using ketamine-based treatments over an extended period have reported symptoms such as frequent urination, urgency, or painful urination. If you experience persistent pelvic pain or changes in your urinary habits during your treatment course, it is vital to inform your provider immediately to prevent long-term complications.

 

How Spravato Differs from IV Ketamine Infusions

While both Spravato (esketamine) and IV ketamine derived from the same parent molecule, they are regulated, administered, and covered by insurance in significantly different ways. Understanding these distinctions is a vital part of the spravato treatment process, as it often determines which option is more accessible for a patient.

 

FDA Approval vs. Off-Label Use

The most significant difference lies in federal regulation. Spravato received FDA approval in 2019 specifically for the treatment of [treatment-resistant depression](https://www.spravatonj.com/Spravato-Effectiveness.html) and major depressive disorder with suicidal ideation. This approval was granted after rigorous clinical trials proved its safety and efficacy for these specific conditions.

 

In contrast, IV ketamine infusions are not FDA-approved for psychiatric disorders. While ketamine is FDA-approved as an anesthetic for surgical procedures, its use for depression is considered “off-label.” This means that while doctors can legally prescribe it, it has not undergone the same specific FDA review process for mental health as Spravato.

 

Delivery Methods

The physical administration of these two treatments requires different clinical setups:

 

• Spravato: Administered as a nasal spray. Patients self-administer the spray under the direct supervision of a healthcare provider. It does not require needles or an IV line.

• IV Ketamine: Administered through an intravenous infusion. A healthcare professional must insert a needle into a vein to deliver the medication directly into the bloodstream over a period of 40 to 60 minutes.

 

Spravato vs. IV Ketamine Comparison Table

| Feature | Spravato (Esketamine) | IV Ketamine Infusions |

| :— | :— | :— |

| FDA Approval | Approved for TRD & MDSI | Off-label for Depression |

| Administration | Nasal Spray (Self-Administered) | Intravenous (IV) Infusion |

| Supervision | Required (2-hour observation) | Required (Continuous monitoring) |

| Insurance Coverage | Often covered by major plans | Rarely covered (Out-of-pocket) |

| REMS Requirement | Strictly regulated via REMS | No REMS requirement |

 

Accessibility and Cost

For many patients, the choice between these options comes down to financial feasibility. Because Spravato is FDA-approved, it is typically covered by private insurance, Medicare, and Medicaid, provided the patient meets specific criteria for treatment-resistant depression.

 

IV ketamine, being off-label, is rarely covered by insurance providers. This often leaves patients responsible for the full cost of infusions, which can range from $400 to $800 per session. For a deeper dive into these nuances, you can read our guide on the [5 critical differences between Spravato and ketamine](https://spravatonj.com/blog/?p=1170).

 

Navigating Costs and Insurance Coverage

Understanding the financial aspect of the spravato treatment process is a vital step in your journey toward mental wellness. While the costs associated with innovative depression treatments can seem complex, most major insurance providers offer coverage for esketamine when clinical necessity is established. At PremierMD, we prioritize transparency and empathy as we help you navigate these administrative hurdles.

 

Insurance Eligibility

To qualify for coverage, most insurance carriers require specific documentation to prove that Spravato is the appropriate next step for your care. A common requirement is prior authorization, a process where our office submits your medical history to your insurer to obtain approval before treatment begins.

 

Additionally, many plans implement step therapy protocols. This typically means the insurance company requires documentation that you have tried a certain number of traditional oral antidepressants—often two or more from different classes—without experiencing significant symptom relief. Our team is experienced in managing these requirements to advocate for your access to care.

 

Out-of-Pocket Expenses

The total cost of treatment varies based on your individual insurance plan’s deductible, copayments, and coinsurance. Because Spravato must be administered under medical supervision, your billing will typically include two components: the cost of the medication itself and the cost of the clinical observation session.

 

[insert table of common insurance providers accepted by PremierMD here]

 

Patient Support Programs

For patients who may face high out-of-pocket costs, there are several assistance options available. We encourage eligible patients to enroll in the Spravato withMe savings card program. For those with commercial insurance, this program can significantly reduce the cost of the medication, often bringing the expense down to as little as $10 per treatment.

 

To help you gain clarity on your specific financial responsibility, we provide a Free Spravato Benefits Check to verify your coverage and identify potential savings programs before you begin your first session.

 

Once you have a clear understanding of the financial landscape, the next step is determining if your clinical history aligns with the medical requirements for treatment.

 

[insert flowchart of insurance approval process here]

 

Integrating Esketamine Protocols within Comprehensive Mental Health Care

Navigating the spravato treatment process involves more than just clinical administration; it requires a sustainable, long-term clinical strategy where financial planning and insurance coordination serve as the foundation for consistent care. By addressing these logistics early, patients can focus entirely on their recovery, knowing that their treatment plan is both clinically sound and financially viable. This integration ensures that the biological intervention is not an isolated event but a cornerstone of a broader, comprehensive mental health strategy.

 

The Value of Supervised Clinical Settings

Professional monitoring is at the heart of the Spravato protocol. Because esketamine can cause temporary changes in blood pressure or transient dissociative effects, patients remain in a certified clinical environment for at least two hours following administration. This period is not merely a regulatory requirement; it is a dedicated window where specialized healthcare professionals monitor vital signs and manage the immediate experience. This high level of supervised care ensures that the patient remains safe and comfortable as the medication begins its work.

 

[insert infographic showing the intersection of neurobiology, clinical monitoring, and patient support here]

 

This observation period also facilitates the critical transition of bridging therapy and neurobiology. Spravato works by modulating NMDA receptors and increasing glutamate signaling, which promotes the growth of new neural connections. This state of heightened neuroplasticity offers a unique opportunity for the brain to bypass the “stuck” patterns of chronic depression. Within a clinical setting, this physiological “reset” is protected from external stressors, allowing the neurobiological shift to take hold effectively as part of the patient’s overall treatment arc.

 

Ultimately, the focus remains on long-term patient outcomes and clinical safety. For individuals facing treatment-resistant cases, the necessity of specialized clinical settings cannot be overstated. These environments provide the structure required to manage complex conditions that have not responded to traditional oral antidepressants. By bridging the gap between advanced neurobiology and tangible patient recovery, supervised Spravato protocols offer a path to stability that is both scientifically grounded and clinically managed. Understanding this rigorous process is the first step toward reclaiming health, leading many to examine the specific criteria for candidacy.

 

Common Questions About the Spravato Process

What happens if I miss a scheduled Spravato session?

Consistency is vital for the effectiveness of esketamine therapy. If you miss a session, you should contact your provider immediately to reschedule. Frequent interruptions can delay the neuroplasticity benefits and may require an adjustment to your induction or optimization schedule to ensure the treatment remains effective.

 

Can I bring my phone or a book to the 2-hour observation period?

You are welcome to bring personal items to help you relax during the observation period. Many patients find that listening to music, using a meditation app, or bringing a light book helps pass the time. Because the medication can cause mild dissociation or sleepiness, it is best to choose activities that do not require intense focus or physical exertion.

 

Are there long-term side effects after completing the full treatment course?

Spravato is generally well tolerated when administered in a controlled clinical setting. While long term risks are rare, clinical monitoring includes checking for potential bladder issues, such as cystitis, which have been reported with chronic ketamine misuse but are strictly monitored within the REMS protocol. Your medical team will track your progress to ensure your safety throughout the maintenance phase.

 

Is Spravato effective for bipolar depression or just MDD?

Currently, Spravato is FDA approved specifically for Treatment Resistant Depression (TRD) and Major Depressive Disorder (MDD) with acute suicidal ideation or behavior. While research into bipolar depression is ongoing, it is not currently a standard indication for this treatment. A comprehensive psychiatric evaluation is the most reliable way to determine if your specific diagnosis qualifies for this protocol.

 

Start Your Path to Wellness

Ready to take the next step in your mental health journey? Contact PremierMD today to schedule your Spravato consultation and see if this innovative treatment is right for you. To begin the process, you can complete a Free Spravato Benefits Check to verify your insurance eligibility and explore how our clinical team can support your long term recovery goals.

Author’s Bio

Dr. David Boguslavsky, MD, is a highly experienced family physician and medical acupuncturist with over two decades of clinical practice, who has emerged as a leader in mental health treatment, particularly in the field of depression. A graduate of Robert Wood Johnson Medical School, Dr. Boguslavsky is board-certified in both Family Medicine and Medical Acupuncture, showcasing his diverse medical expertise. His extensive experience spans a wide range of medical care, from acute illnesses to chronic condition management, with a particular focus on preventative care and pain treatment.
Notably, Dr. Boguslavsky has pioneered innovative approaches to depression treatment, having administered over 10,000 Spravato treatments, establishing himself as one of the foremost experts in this cutting-edge therapy. His unique blend of traditional Western medicine, Eastern acupuncture techniques, and advanced psychiatric treatments allows him to offer comprehensive, personalized care to his patients at PremierMD and Spravato Treatment Centers of NJ. Fluent in English and Russian, Dr. Boguslavsky brings a multifaceted approach to healthcare, combining the latest medical technologies with time-honored principles of doctor-patient relationships to address both physical and mental health needs.